Journals / Türkiye Parazitoloji Dergisi / 2011 / Cilt: 35 - Sayı: 3

IFA ve ELISA yöntemleri ile çocuk visserallLeishmaniasis serolojik izlemi

Serological monitoring of paediatric visceral leishmaniasis by IFA and ELISA methods

Pages
125–128
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Mean ELISA optical density values before and after treatment were: 0.78±0.36 (0.26-1.76) and 0.38±0.24 (0.09-0.83) respectively, (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Visceral leishmaniasis (VL) is endemic in all Mediterranean countries including Turkey, and children are at greater risk than adults in endemic areas.
📊
Key Findings & Data:The patients were monitored clinically and serologically (range: 20-500 days) during and after treatment.
💡
Conclusion & Impact:Mean ELISA optical density values before and after treatment were: 0.78±0.36 (0.26-1.76) and 0.38±0.24 (0.09-0.83) respectively, (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Visceral leishmaniasis (VL) is endemic in all Mediterranean countries including Turkey, and children are at greater risk than adults in endemic areas. In VL patients, serological assays are considered to be sensitive for the diagnosis and/or follow up. The aim of this study was to assess the usefulness of serology for following up of childhood VL in Turkey. Methods: Sera obtained from twenty parasitologically confirmed children with VL were tested using IFAT and ELISA. The patients were monitored clinically and serologically (range: 20-500 days) during and after treatment. All VL patients were treated with meglumine antimonate. Results: Anti-Leishmania antibodies in successfully treated VL patients showed a steep decline but, in three patients who had relapsed, an increase was detected. Significantly lower values were observed after treatment with both serological techniques. Mean ELISA optical density values before and after treatment were: 0.78±0.36 (0.26-1.76) and 0.38±0.24 (0.09-0.83) respectively, (p

Özet

Amaç: Visseral leishmaniasis (VL) Türkiye'nin de içinde bulunduğu Akdeniz ülkelerinde yaygın olarak görülür ve endemik bölgelerde çocuklar yetişkinlere göre daha büyük risk altındadırlar. VL hastalarında serolojik testler tanı ve/veya izlem açısından hassas olarak kabul edilmektedir. Bu çalışmanın amacı, Türkiye'de çocukluk çağı VL izlemi açısından serolojinin yararlılığını değerlendirmektir. Yöntemler: VL olduğu parazitolojik olarak doğrulanan yirmi çocuktan alınan serumlar IFAT ve ELISA testleriyle çalışıldı. Hastalar; tedavi süresince ve tedavi sonrasında (aralık: 20–500 gün) serolojik ve klinik olarak izlendi. Tüm VL hastaları meglumin antimonat ile tedavi edildi. Bulgular: Başarıyla tedavi edilen VL hastalarında anti-Leishmania antikorlarında keskin bir düşüş, nüks olan üç hastada ise antikorlarda artış tespit edildi. Anlamlı düşük değerler her iki serolojik teknikle tedavi sonrasında gözlendi. Tedavi öncesi ve sonrası ortalama ELISA OD değerleri: sırasıyla 0.78±0.36 (0.26-1.76) ve 0.38±0.24 (0.09-0.83) (p

🔖

Cite This Article

ŞAKRU, N., ÖZENSOY, S. T., ÖZBER, Y., KORKMAZ, M. (2022). IFA ve ELISA yöntemleri ile çocuk visserallLeishmaniasis serolojik izlemi. Türkiye Parazitoloji Dergisi, Cilt: 35 - Sayı: 3, 125–128. https://ajindex.com/articles/630449

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Desjeux P. Leishmaniasis: Current situation and new perspectives. Comp Immunol Microbiol Infect Dis 2004
  2. [CrossRef] 2) Kafetzis DA. An overview of paediatric leishmaniasis. J Postgrad Med 2003
  3. [CrossRef] 3) Hailu A. Pre- and post-treatment antibody levels in visceral leishmaniasis. Trans R Soc Trop Med Hyg 1990
  4. [CrossRef] 4) Kumar R, Pai K, Pathak K, Sundar S. Enzyme-linked immunosorbent assay for recombinant K39 antigen in diagnosis and prognosis of Indian visceral leishmaniasis. Clin Diagn Lab Immunol 2001
  5. [CrossRef] 5) Kumar P, Pai K, Tripathi K, Pandey HP, Sundar S. Immunoblot analysis of the humoral immune response to Leishmania donovani polypeptides in cases of human visceral leishmaniasis: its usefulness in prognosis. Clin Diagn Lab Immunol 2002
  6. [CrossRef] 6) Millesimo M, Zucca M, Caramello P, Savoia D. Evaluation of the immune response in visceral leishmaniasis. Diagn Microbiol Infect Dis 1996
  7. [CrossRef] 7) Sundar S, Rai M. Laboratory diagnosis of visceral leishmaniasis. Clin Diagn Lab Immunol 2002
  8. [CrossRef] 8) de Korte PM, Harith AE, Dereure J, Huigen E, Faucherre V, van der Kaay HJ. Introduction of an improved direct agglutination test for the detection of Leishmania infantum infection in southern France. Parasitol Res 1990
  9. [CrossRef] 9) Abranches P, Silva-Pereira MC, Conceição-Silva FM, Santos-Gomes GM, Janz JG. Canine leishmaniasis: pathological and ecological factors influencing transmission of infections. J Parasitol 1991
  10. [CrossRef] 10) Özbel Y, Oksam L, Özensoy S, Turgay N, Alkan MZ, Jaffe CL, et al. A survey on canine leishmaniasis in western Turkey by parasite, DNA and antibody detection assays. Acta Trop 2000
  11. Ozensoy S, Ozbel Y, Turgay N, Alkan MZ, Gul K, Gilman-Sachs A, et al. Serodiagnosis and epidemiology of visceral leishmaniasis in Turkey. Am J Trop Med Hyg 1998
  12. [CrossRef] 12) Özensoy Töz S, Özbel Y, Atay MG, Ertabaklar H, Şakru N, Taylan Özkan A, et al. Application of Polymerase Chain Reaction (PCR) for Diagnosis of Leishmaniasis in Clinical Samples Obtained from Human and Dogs. Turkiye Parazitol Derg 2002
  13. WHO Technical Report Series: 949, Control of the Leishmaniases. Report of a meeting of the WHO Expert Committee on the Control of Leishmaniases, Geneva, 22–26 March 2010. 14) Maltezou HC, Siafas C, Mavrikou M, Spyridis P, Stavrinadis C, Karpathios T, et al. Visceral leishmanias